Lantern Pharma Earnings Call Transcripts
Fiscal Year 2026
-
withZeta.ai is an advanced AI platform accelerating rare cancer drug discovery by integrating multi-agent tools, dynamic knowledge graphs, and real-time molecular design. The platform enables rapid research, collaboration, and budget planning, aiming to transform biomedical innovation.
-
Lantern leverages a proprietary AI platform to accelerate cancer drug development, with three clinical-stage drugs and a new subsidiary targeting neuro-oncology. The platform is now accessible to external researchers, opening significant market opportunities and generating revenue, while multiple FDA designations and upcoming data releases highlight strong clinical momentum.
-
AI-driven platforms have accelerated oncology drug development, reducing timelines and costs while enabling precision targeting and multiple FDA designations. Key catalysts include upcoming data for LP-300 and LP-184, the launch of Starlight Therapeutics, and the commercialization of withZeta.ai.
Fiscal Year 2025
-
Clinical programs advanced with strong trial results and multiple FDA designations, while AI platforms expanded commercially. Operating expenses fell 19% year-over-year, but additional funding is needed as cash runway extends only to late Q3 2026.
-
LP-184 has completed a successful phase I-A trial, showing strong safety, durable disease control, and promising anti-tumor activity in heavily pretreated patients with DNA repair deficiencies. The drug's mechanism targets tumors with high PTGR1 and DNA repair mutations, supporting precision medicine and combination strategies.
-
Q3 2025 marked a pivotal quarter with strong clinical progress, notably a 48% benefit rate in LP-184's phase I-A trial, and commercial advances in AI platforms. Net loss narrowed to $4.2M, with $12.4M in cash providing runway into Q3 2026.
-
Five monetization opportunities were outlined, including three clinical-stage drugs, an open-access AI platform, and a neuro-oncology spinout. Lead assets target high-value cancer indications, with multiple fast track and orphan designations, and the company is launching new AI tools for rare cancer drug development.
-
AI-driven oncology drug development is advancing with three clinical assets, robust patent protection, and a public AI platform module. Key clinical milestones include durable responses in NSCLC and B-cell lymphoma, with a strong financial position and upcoming data releases.
-
Q1 2025 saw major clinical and AI platform progress, with reduced net loss and strong cash reserves. Key trials for LP-184 and LP-300 are advancing, and commercialization of RADR AI modules is planned this year. Market opportunities and AI-driven efficiencies remain strong.
Fiscal Year 2024
-
AI-driven oncology drug development is accelerating, with multiple clinical programs advancing and key data readouts expected in 2024. Cash reserves of $24 million provide at least 12 months of runway, but additional funding will be needed.
-
Advanced three AI-guided oncology drugs in clinical trials, expanded into Asia, and secured FDA Fast Track and rare pediatric disease designations for LP-184. Maintained a strong cash position with $28.1 million, supporting a projected runway into late 2025.
-
Q2 2024 saw strong clinical progress, highlighted by an 86% clinical benefit rate in the HARMONIC trial and continued advancement of AI-driven oncology programs. Net loss was $4.96M, with $33.3M in cash supporting operations into Q3 2025.